Oshikoya, Kazeem A.
Carroll, Robert
Aka, Ida
Roden, Dan M.
Van Driest, Sara L. http://orcid.org/0000-0003-2580-1405
Funding for this research was provided by:
National Center for Advancing Translational Sciences (UL1 TR000445, KL2 TR000446)
Burroughs Wellcome Fund (1015006)
Doris Duke Charitable Foundation (2017075)
National Institute of General Medical Sciences (5T32 GM007569)
Article History
First Online: 27 March 2019
Compliance with Ethical Standards
:
: The study was reviewed by the Vanderbilt Institutional Review Board and determined to be non-human subjects research.
: Dr. Van Driest has been an invited speaker to Merck. Dr. Oshikoya, Dr. Carroll, Ms. Aka, and Dr. Roden have no conflicts of interest that are directly relevant to the content of this article.
: This work used a dataset from Vanderbilt University Medical Center’s BioVU, which is supported by the Vanderbilt Institute for Clinical and Translational Research (VICTR) and the National Institutes of Health (NIH) National Center for Advancing Translational Sciences grants UL1 TR000445. This work was also supported by KL2 TR000446 (SLV), Burroughs Wellcome Fund Innovation in Regulatory Science Award 1015006 (SLV), Doris Duke Clinical Scientist Development Award 2017075 (SLV), and NIH/National Institute of General Medical Sciences Clinical Pharmacology Training Program 5T32 GM007569 (KAO).